Rivaroxaban versus standard anticoagulation for acute venous thromboembolism in childhood. Design of the EINSTEIN-Jr phase III study

Anthonie W.A. Lensing*, Christoph Male, Guy Young, Dagmar Kubitza, Gili Kenet, M. Patricia Massicotte, Anthony Chan, Angelo C. Molinari, Ulrike Nowak-Goettl, Ákos F. Pap, Ivet Adalbo, William T. Smith, Amy Mason, Kirstin Thelen, Scott D. Berkowitz, Mark Crowther, Stephan Schmidt, Victoria Price, Martin H. Prins, Paul Monagle

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

30 Scopus citations

Fingerprint

Dive into the research topics of 'Rivaroxaban versus standard anticoagulation for acute venous thromboembolism in childhood. Design of the EINSTEIN-Jr phase III study'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science